Citius Pharmaceuticals, Inc.
CTXR
$0.58
-$0.02-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.11M | 5.61M | 3.94M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.11M | 5.61M | 3.94M | -- | -- |
| Cost of Revenue | 1.61M | 1.12M | 789.20K | -- | -- |
| Gross Profit | 5.50M | 4.49M | 3.15M | -- | -- |
| SG&A Expenses | 56.94M | 54.14M | 31.46M | 29.37M | 30.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.47M | 61.76M | 40.88M | 38.53M | 41.14M |
| Operating Income | -57.37M | -56.15M | -36.93M | -38.53M | -41.14M |
| Income Before Tax | -57.98M | -54.89M | -37.80M | -38.68M | -41.14M |
| Income Tax Expenses | 189.90K | 561.40K | 1.06M | 1.06M | 936.60K |
| Earnings from Continuing Operations | -58.17 | -55.45 | -38.85 | -39.74 | -42.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 11.89M | 9.25M | 2.97M | 2.31M | 1.81M |
| Net Income | -46.27M | -46.20M | -35.89M | -37.43M | -40.26M |
| EBIT | -57.37M | -56.15M | -36.93M | -38.53M | -41.14M |
| EBITDA | -46.21M | -55.00M | -36.36M | -38.52M | -41.14M |
| EPS Basic | -2.13 | -2.59 | -2.92 | -3.84 | -4.97 |
| Normalized Basic EPS | -1.13 | -1.47 | -1.68 | -2.25 | -2.89 |
| EPS Diluted | -2.13 | -2.59 | -2.92 | -3.84 | -4.97 |
| Normalized Diluted EPS | -1.13 | -1.47 | -1.68 | -2.25 | -2.89 |
| Average Basic Shares Outstanding | 87.24M | 72.08M | 58.28M | 44.28M | 34.31M |
| Average Diluted Shares Outstanding | 87.24M | 72.08M | 58.28M | 44.28M | 34.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |